Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals, Inc.    ARWR

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arrowhead Pharmaceuticals : Announces Closing of Agreement with Takeda

11/25/2020 | 07:31am EST

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020, has now closed. Closing of the transaction was contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.


© Business Wire 2020
All news about ARROWHEAD PHARMACEUTICALS, INC.
01/19INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Arrowhe..
MT
01/19ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2021 First Quarter Results
BU
01/15INSIDER TRENDS : Arrowhead Pharmaceuticals Insider Sale Interrupting 90-Day Buy ..
MT
01/13ARROWHEAD PHARMACEUTICALS : Significant Insider Selling in Shares of Arrowhead P..
MT
01/12INSIDER TRENDS : Arrowhead Pharmaceuticals Insider Sale Scales Back 90-Days of B..
MT
01/11ARROWHEAD PHARMACEUTICALS : Significant Insider Selling Continues at Arrowhead P..
MT
01/08ARROWHEAD PHARMACEUTICALS : Insider Sales at Arrowhead Pharmaceuticals (ARWR) ar..
MT
01/08INSIDER TRENDS : 90-Days of Insider Buying at Arrowhead Pharmaceuticals Eased Ba..
MT
01/07INSIDER TRENDS : Arrowhead Pharmaceuticals Insider Sale Scales Back 90-Days of B..
MT
01/07INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Arrowhead Ph..
MT
More news
Financials (USD)
Sales 2021 198 M - -
Net income 2021 -8,44 M - -
Net cash 2021 286 M - -
P/E ratio 2021 -335x
Yield 2021 -
Capitalization 8 433 M 8 433 M -
EV / Sales 2021 41,1x
EV / Sales 2022 47,1x
Nbr of Employees 232
Free-Float 96,5%
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 82,46 $
Last Close Price 82,07 $
Spread / Highest target 21,8%
Spread / Average Target 0,48%
Spread / Lowest Target -58,6%
EPS Revisions
Managers and Directors
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Kenneth Allen Myszkowski Chief Financial Officer
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS, INC.6.96%8 433
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148